Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format.
about
Deubiquitinases sharpen substrate discrimination during membrane protein degradation from the ERModulation of the p53/MDM2 interplay by HAUSP inhibitorsDeubiquitylase, deSUMOylase, and deISGylase activity microarrays for assay of substrate preference and functional modifiersDeubiquitinating enzymes as promising drug targets for infectious diseases.Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53.Role of ubiquitylation and USP8-dependent deubiquitylation in the endocytosis and lysosomal targeting of plasma membrane KCa3.1.Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cellsA small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Post-translational O-GlcNAcylation is essential for nuclear pore integrity and maintenance of the pore selectivity filter.USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancerThe Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death.Measuring activity in the ubiquitin-proteasome system: from large scale discoveries to single cells analysisThe WD40-repeat protein-containing deubiquitinase complex: catalysis, regulation, and potential for therapeutic intervention.The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeuticsDifferential loss of prolyl isomerase or chaperone activity of Ran-binding protein 2 (Ranbp2) unveils distinct physiological roles of its cyclophilin domain in proteostasis.Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218).Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.Modulation of Retrograde Trafficking of KCa3.1 in a Polarized EpitheliumChemical and semisynthetic approaches to study and target deubiquitinases.Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication.Cell Lysate-Based AlphaLISA Deubiquitinase Assay Platform for Identification of Small Molecule Inhibitors.Using antiubiquitin antibodies to probe the ubiquitination state within rhTRIM5α cytoplasmic bodies.Bioluminescence assay platform for selective and sensitive detection of Ub/Ubl proteases.Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60.Grb2-Mediated Recruitment of USP9X to LAT Enhances Themis Stability following Thymic Selection.Discovery and characterization of highly potent and selective allosteric USP7 inhibitors.Oxidation of SQSTM1/p62 mediates the link between redox state and protein homeostasis.Targeting deubiquitinase USP28 for cancer therapy.Fluorescence-based active site probes for profiling deubiquitinating enzymes
P2860
Q24311975-5EA1585A-AFA9-46C6-B205-B1E1031E8FD2Q28075457-CE971976-7E08-44C5-A119-0D9E3FC6358EQ33721740-726A5C97-0023-4B44-A3B1-98914928FDA1Q33836097-F7E5C207-07DD-4B15-9544-9482BFC39A59Q34916951-F944A05F-82B6-4840-A1E2-D9B8B355DAD0Q35497084-F23FBF2A-04CB-4993-9BB7-1DC610645AB5Q35559055-7E5645B3-20F0-4B5C-9D46-375F62778027Q35934305-B0703ED1-B8BF-4CDB-BB5B-B0850125FA42Q36338365-96EA98E7-25A4-46E9-BDAE-FD9C8EEC888CQ36455332-17C5919C-92B8-4622-9490-321A8A4395F7Q36599308-A8E90B16-DCF1-4FA9-9A8A-A72C6F4D0510Q36674724-15FBF10D-A502-4FAF-8FCF-9F2195DBE4E5Q37136216-1F39F93E-4693-45FC-8CD6-6C13FDB6940AQ37496493-F65E8A55-CD1F-4FD7-A62A-98670DA3CBDFQ37517626-B55FFDD3-0FC4-48FB-A934-291FD8EE8E7FQ37596297-A73D8E43-5A85-48DC-84E3-0AE83869F653Q38181181-539190B1-2FE2-43D6-9910-94EF7EDA2260Q38196269-5DE22667-8C45-4E64-8A2F-6BCB9C01346DQ38645650-960DD35E-86FE-4AE1-AE90-DB30B2D762BAQ38799376-BEE201EE-9847-4904-A432-095F6554A5CDQ39171781-0EA0E2CA-2D70-4D11-9EE5-89EA77B8A361Q40072442-2AA5BFB8-E312-4BC6-BE71-1FDF0E472837Q41824768-257A1785-DEC5-4926-A0E6-25EDC20F6CCDQ42483578-22D07BE7-1830-4E70-8BE5-F0B6BF51A37DQ47098444-A78DD322-0B88-4F44-948D-E3CF48B89FF5Q47135501-4FEA8EA5-6D45-447D-8320-CD4EA5A5979EQ47298570-42A73693-3234-47A9-AA72-2CA56081982FQ48188572-FD83735D-49EE-45BB-BC95-3B3F33879CAEQ48223380-CFCA5F39-728F-4D97-ADA6-A7F0A0EE51A7Q50130212-3343F01F-6FB3-475D-94AC-591FCFC17B76Q58214389-64D4BD56-056E-47F3-9B29-ECAC17DD479E
P2860
Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Characterization of selective ...... -based multiplex assay format.
@en
type
label
Characterization of selective ...... -based multiplex assay format.
@en
prefLabel
Characterization of selective ...... -based multiplex assay format.
@en
P2093
P2860
P356
P1476
Characterization of selective ...... -based multiplex assay format.
@en
P2093
Benjamin Nicholson
Craig Leach
Michael R Mattern
Nigora S Isamiddinova
Raymond J Peroutka
Seth J Goldenberg
Xufan Tian
P2860
P304
P356
10.1089/ADT.2010.0317
P577
2010-12-06T00:00:00Z